Back to search results

Study of Zyn Nicotine Pouches for Smoking Reduction

This study is looking at how well tobacco-free nicotine pouches, specifically Zyn, can help people switch from smoking cigarettes or reduce the number of cigarettes they smoke. Researchers are testing two different strengths of Zyn pouches: a high nicotine dose (6 mg) and a low nicotine dose (3 mg). You might be able to join if you are 21 or older, currently smoke cigarettes regularly, and haven't used tobacco-free nicotine pouches much before. The study aims to see if using these pouches helps people smoke less or stop smoking entirely. The current recruitment status is unclear.

Study design
This is an interventional study with a planned enrollment of 50 participants. Participants will be randomly assigned to receive either high or low nicotine Zyn pouches.
What's involved
You would attend two in-person visits in Charleston, provide breath and cheek swab samples, and use a 28-day supply of nicotine pouches. You will also answer questions about your tobacco use at the visits and one month after your final visit.
Compensation
Not stated in the trial record.
Follow-up
Your smoking habits will be checked at Day 28 and Day 56, and you will answer questions about tobacco use one month after your final visit.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06678789

Evaluation of Low and High Nicotine Tobacco Free Nicotine Pouches

Recruiting
NAAges 21+Interventional
Medical University of South Carolina
~50 participants
Updated 2026-08-20 on ClinicalTrials.gov
What's tested:High Nicotine DoseLow Nicotine Dose

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Switching
Measured over Day 28 and Day 56
+1 more outcome measured

Conditions

Cigarette Smoking
Nicotine Dependence
Smoking Cessation

Explore related trials

Cigarette Smoking

Where it's being run

1 sites across 1 states
South Carolina1

Study leadership

  • Amanda Palmer, PhD. · PRINCIPAL_INVESTIGATOR · Medical University of South Carolina

Who to contact

Talia Ogretman
[email protected]
843-259-8111
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 21+
current cigarette smoking (25+ days per previous month, 5 or more cigarettes/day, for greater than 1yr, greater than 100 lifetime cigarettes)
have not used TNFPs more than 5 times during their lifetime
willing and able to attend 2 in-person visits in Charleston (to assess biomarkers)
have internet access

Exclusion

Lack of proficiency in English.
Use of other combustible tobacco products (i.e., cigars, cigarillos, hookahs) and/or other non-combusted nicotine/tobacco products (i.e., e-cigarettes, smokeless tobacco) in the past 30 days.
Current use of smoking cessation medications (i.e., varenicline, bupropion, nicotine replacement therapy).
Use of marijuana within the past month, and unwillingness to abstain from marijuana during course of study.
Medical conditions contraindicated to NRT use (including pregnancy, breastfeeding, and nursing, past month myocardial infarction, current untreated cardiac arrhythmia, current severe angina, current uncontrolled severe vascular disease).

What this trial measures

  • SwitchingDay 28 and Day 56

    Switching will be defined at 7-day point-prevalence biochemically-confirmed abstinence from cigarettes alongside self-reported use of nicotine pouches. Non-responders and missing data will be coded as smoking.

  • Smoking ReductionDay 28 and Day 56

    Baseline and daily survey data will be used to calculate the change of smoking (average cigarettes per day) between groups from baseline to end of sampling.